Edition:
United States

Novo Nordisk A/S (NOVOb.CO)

NOVOb.CO on Copenhagen Stock Exchange

316.20DKK
9:16am EST
Change (% chg)

kr.5.50 (+1.77%)
Prev Close
kr.310.70
Open
kr.318.20
Day's High
kr.318.20
Day's Low
kr.312.75
Volume
1,304,651
Avg. Vol
2,517,315
52-wk High
kr.354.80
52-wk Low
kr.265.15

Chart for

About

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity... (more)

Overall

Beta: 1.44
Market Cap(Mil.): kr.576,064.31
Shares Outstanding(Mil.): 1,912.56
Dividend: 3.00
Yield (%): 2.61

Financials

  NOVOb.CO Industry Sector
P/E (TTM): 19.13 29.45 30.88
EPS (TTM): 15.74 -- --
ROI: 72.95 14.34 13.80
ROE: 81.27 15.85 15.29

Swiss stocks - Factors to watch on Jan. 16

Jan 16 - The Swiss blue-chip SMI was seen opening 0.4 percent higher at 8,856 points on Wednesday, according to premarket indications by bank Julius Baer.

Jan 16 2019

BRIEF-DKSH Holding Signs Distribution Agreement With Novo Nordisk Pharmatech

* SIGNS DISTRIBUTION AGREEMENT WITH NOVO NORDISK PHARMATECH FOR ELEVEN MARKETS IN ASIA PACIFIC Source text - https://bit.ly/2AMIrN4 Further company coverage: (Gdynia Newsroom)

Jan 16 2019

Novartis, China's Gan & Lee push into insulin amid diabetes epidemic

ZURICH Swiss drugmaker Novartis aims to become a big player in supplying insulin to swelling numbers of diabetics, signing a deal with China's Gan & Lee on versions of three blockbuster brands as the U.S. government is seeking to slash insulin costs.

Dec 19 2018

UPDATE 1-Novartis, China's Gan & Lee push into insulin amid diabetes epidemic

* U.S. aims to tackle high insulin prices (Adds bullets, comment from company, FDA details)

Dec 19 2018

Novartis links with China's Gan & Lee in global insulin push

ZURICH, Dec 19 Swiss drugmaker Novartis aims to become a big player in supplying insulin to diabetics, signing a deal with China's Gan & Lee covering versions of three blockbuster brands just as the U.S. government is seeking to slash insulin costs.

Dec 19 2018

Patients and industry fret over drug supplies, if no Brexit deal

LONDON Consumers and the pharmaceuticals industry alike are anxious about medicine supplies, if there is no deal on Britain's departure from the European Union.

Nov 13 2018

Patients and industry fret over drug supplies, if no Brexit deal

LONDON, Nov 14 Consumers and the pharmaceuticals industry alike are anxious about medicine supplies, if there is no deal on Britain's departure from the European Union.

Nov 13 2018

Upbeat sales lift Novo Nordisk as drugmaker weathers U.S. pricing pressure

COPENHAGEN Novo Nordisk , the world's top maker of diabetes drugs, reported encouraging sales of its main growth drivers on Thursday as it announced more job cuts amid a restructuring to cope with intensifying pricing pressure in the United States.

Nov 01 2018

UPDATE 2-Upbeat sales lift Novo Nordisk as drugmaker weathers U.S. pricing pressure

* Expands share buyback programme (Adds CEO comment, details, background)

Nov 01 2018

Novo Nordisk Q3 profit slightly below forecast, nudges up 2018 sales outlook

COPENHAGEN, Nov 1 Denmark's Novo Nordisk , the world's top maker of diabetes drugs, posted third-quarter operating profit slightly below forecasts on Thursday, but lifted the lower end of its sales forecast for the year.

Nov 01 2018

Earnings vs. Estimates